Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.
Am J Cardiovasc Drugs
; 21(6): 589-593, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1144418
ABSTRACT
The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vasodilator Agents
/
Nitroglycerin
/
COVID-19
/
Heart Failure
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Am J Cardiovasc Drugs
Journal subject:
Vascular Diseases
/
Cardiology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
S40256-021-00474-w
Similar
MEDLINE
...
LILACS
LIS